MARKET

ESPR

ESPR

Esperion Therape
NASDAQ
1.520
-0.030
-1.94%
After Hours: 1.521 +0.001 +0.06% 19:59 03/12 EDT
OPEN
1.570
PREV CLOSE
1.550
HIGH
1.580
LOW
1.500
VOLUME
7.16M
TURNOVER
--
52 WEEK HIGH
3.940
52 WEEK LOW
1.500
MARKET CAP
300.73M
P/E (TTM)
-5.4993
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ESPR last week (0303-0307)?
Weekly Report · 2d ago
Based on the provided financial report, the title of the article is: "Esperion Therapeutics, Inc. (ESPR) Annual Report (Form 10-K) for the fiscal year ended December 31, 2024
Press release · 5d ago
Esperion Therapeutics Price Target Maintained With a $4.00/Share by Citizens Capital Markets
Dow Jones · 03/05 15:14
Citizens Capital Markets Reiterates Market Outperform on Esperion Therapeutics, Maintains $4 Price Target
Benzinga · 03/05 15:04
Esperion’s Promising Future: Strategic Partnerships and Product Innovations Drive Buy Rating
TipRanks · 03/05 11:28
Sell Rating for Esperion Amidst US Market Underperformance and Competitive Pressures
TipRanks · 03/05 10:18
ESPR's Q4 Loss Narrower Than Expected, Revenues Increase Y/Y
Barchart · 03/05 09:00
Esperion Therapeutics Reports Strong Revenue Growth in 2024
TipRanks · 03/05 03:58
More
About ESPR
Esperion Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). The Company's products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company's NEXLETOL and NEXLIZET (bempedoic acid and ezetimibe) tablets are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD). Its NEXLETOL is an ATP Citrate Lyase (ACL), inhibitor that lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine. Its Pipeline product include Next Generation ACLYi.

Webull offers Esperion Therapeutics Inc stock information, including NASDAQ: ESPR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ESPR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ESPR stock methods without spending real money on the virtual paper trading platform.